MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
IRD — Opus Genetics, Inc. Common Stock
NasdaqOpus Genetics, Inc. Common Stock
$4.38
-0.20(-4.37%)
- O
- 4.57
- H
- 4.64
- L
- 4.34
- V
- 2.53M
⏱️ End-of-day dataAs of Oct 5, 2026
Chart
About IRD
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateNov 6, 2020
Employees28
Stock ExchangeNasdaq
Ticker SymbolIRD
Websitehttps://www.opusgtx.com
Key Financial Statistics
| Market Cap | $381.04M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.70 - $7.07 |
| 52-Week Avg Volume | 1.19M |
| VWAP | $4.45 |
| Transactions | 16,510 |
| Total Recorded Bars | 5,255 days |